Moderna Inc. (MRNA)

AI Score

Unlock

26.66

0.46 (1.76%)

At close: Apr 14, 2025, 1:06 PM

1.76% (1D)

Bid	25.35
Market Cap	10.29B
Revenue (ttm)	3.23B
Net Income (ttm)	-3.56B
EPS (ttm)	-9.28
PE Ratio (ttm)	-2.87
Forward PE	-5.07
Analyst	Hold

Ask	26.82
Volume	3,089,537
Avg. Volume (20D)	13,175,265.1
Open	26.88
Previous Close	26.20
Day's Range	26.24 - 26.96
52-Week Range	23.15 - 170.47
Beta	2.23

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 7, 2018

Employees 5,800

Stock Exchange NASDAQ

Ticker Symbol MRNA

Website https://www.modernatx.com

Full Company Profile

Analyst Forecast

According to 20 analyst ratings, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $50.5, which is an increase of 89.39% from the latest price.

Stock Forecasts

Next Earnings Release

Moderna Inc. is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

-7%

Shares of vaccine stocks are trading lower on repo... Unlock content with Pro Subscription

1 month ago

+15.94%

Moderna shares are trading higher after CEO Stephane Bancel Disclosed a share purchase.

News

Just now · zacks.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

3 days ago · accessnewswire.com

Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report ...

5 days ago · fool.com

Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%.

6 days ago · accessnewswire.com

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influ...

1 week ago · fool.com

Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (PFE 0.77%) and Moderna (MRNA 2.21%). These two vaccine makers mad...

1 week ago · fool.com

FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?

Moderna (MRNA 2.21%) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later s...